JGB1741
CAS No. 1256375-38-8
JGB1741 ( ILS-JGB-1741 )
产品货号. M27505 CAS No. 1256375-38-8
JGB1741 是一种有效的选择性 SIRT1 抑制剂,IC50 为 15 μM。 JGB1741 调节 Bax/Bcl2 比率、细胞色素 c 释放和 PARP 裂解,并增加乙酰化 p53 水平,导致 p53 介导的细胞凋亡。 JGB1741可用于乳腺癌研究。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥2366 | 有现货 |
|
| 10MG | ¥3791 | 有现货 |
|
| 25MG | ¥5943 | 有现货 |
|
| 50MG | ¥8138 | 有现货 |
|
| 100MG | ¥10530 | 有现货 |
|
| 500MG | ¥21240 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称JGB1741
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述JGB1741 是一种有效的选择性 SIRT1 抑制剂,IC50 为 15 μM。 JGB1741 调节 Bax/Bcl2 比率、细胞色素 c 释放和 PARP 裂解,并增加乙酰化 p53 水平,导致 p53 介导的细胞凋亡。 JGB1741可用于乳腺癌研究。
-
产品描述JGB1741 is a potent and selective inhibitor of SIRT1 with an IC50 of 15 μM. JGB1741 modulates Bax/Bcl2 ratio, cytochrome c release and PARP cleavage and increases the acetylated p53 levels leading to p53-mediated apoptosis. JGB1741 can be used in studies about breast cancer.(In Vitro):JGB1741 (1-10000 nM) inhibits the cell proliferation of K562, HepG2 and MDA-MB 231 cell lines. JGB1741 (0.01-1 μM) induces apoptosis of MDA-MB 231 and shows a cell cycle arrest at G1 phase with more cells entering into sub G0/G1 phase. JGB1741 (0.01-1 μM) increases the global acetylation of H3K9, acetylated p53K382 levels and p53 expression.
-
体外实验JGB1741 (ILS-JGB-1741; 1-10000 nM; 24 h) inhibits MDA-MB 231 cell proliferation. JGB1741 (0.01-1 μM; 24 h) induces apoptosis of MDA-MB 231 cells. JGB1741 (0.01-1 μM; 24 h) shows a cell cycle arrest at G1 phase with more and more cells entering into sub G0/G1 phase. JGB1741 (0.01-1 μM; 24 h) shows an increase in the global acetylation of H3K9, p53 expression and acetylated p53K382 levels. Cell Proliferation Assay Cell Line:K562, HepG2 and MDA-MB 231 cell lines Concentration:1, 10, 50, 100, 500, 1000, 10000 nM Incubation Time:24 hours Result:Inhibited MDA-MB 231 cell proliferation more potently with an IC50 of 0.5 μM than K562 and HepG2 cell proliferation (IC50>1 μM).Apoptosis Analysis Cell Line:MDA-MB 231 cells Concentration:0.01, 0.1, 0.5, 1 μM Incubation Time:Result:Showed an increase in the percent apoptotic cells in a dose-dependent fashion with ~70% apoptosis at 1 μM concentration.Cell Cycle Analysis Cell Line:MDA-MB 231 cells Concentration:0.01, 0.1, 0.5, 1 μM Incubation Time:Result:Showed a cell cycle arrest at G1 phase with more and more cells entering into sub G0/G1 phase, the apoptotic phase, in a dose-dependent fashion.Western Blot Analysis Cell Line:MDA-MB 231 cells Concentration:0.01, 0.1, 0.5, 1 μM Incubation Time:Result:Caused a dose-dependent increase in the global acetylation of H3K9. Showed an increase in both p53 expression and acetylated p53K382 levels.
-
体内实验——
-
同义词ILS-JGB-1741
-
通路Chromatin/Epigenetic
-
靶点Sirtuin
-
受体Aurora B
-
研究领域——
-
适应症——
化学信息
-
CAS Number1256375-38-8
-
分子量440.56
-
分子式C27H24N2O2S
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 5 mg/mL (11.35 mM)
-
SMILESC(NCC1=CC=CC=C1)(=O)C=2C3=C(SC2/N=C/C=4C5=C(C=CC4O)C=CC=C5)CCCC3
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.1. Naga Rajiv Lakkaniga,et al. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression.Eur J Med Chem. 2020 Jul 12;203:112589.
产品手册
关联产品
-
Neodiosmin
新地奥司明水溶性差,但具有良好的脱苦作用,是一种强抗氧化剂,在食品、饮料和药物制剂中具有潜在的应用前景。
-
MC3482 B
MC3482是一种特异性sirtuin5 (SIRT5) 抑制剂。
-
Pristimerin
Pristimerin 具有抗癌活性,Pristimerin 治疗可能是通过逆转缺氧诱导的干细胞特征和癌细胞 EMT 来抑制缺氧诱导的转移的潜在策略。
021-51111890
购物车()
sales@molnova.cn

